drugset / Trial / NCT03446625

Resveratrol as a Preventive Treatment of OHSS

NCT03446625

Phase 3 Completed 70 enrolled IVI Madrid
RandomizedParallel-groupDouble-blindPrevention

Summary

Evaluation of resveratrol treatment oh ovarian hyperstimulation syndrome in egg donors

Timeline

Start
2018-03-13
Primary completion
2018-10-01
Completion
2019-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Resveratrol Small molecule 2 g Oral

Indications